Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)
European Journal of Cancer2020Vol. 141, pp. 21–29
Citations Over TimeTop 10% of 2020 papers
Yungan Tao, Anne Aupérin, Xu-Shan Sun, Christian Sire, Laurent Martin, Alexandre Coutté, Cédrik Lafond, J. Miroir, X. Liem, Frédéric Rolland, Caroline Even, France Nguyen, Esma Saâda, Aline Maillard, Natacha Colin-Batailhou, Juliette Thariat, J. Guigay, Jean Bourhis
Abstract
The avelumab-cetuximab-RT combination was tolerable for patients with LA-SCCHN, and the approval was given for continuing the trial without modification. CLINICALTRIAL.GOV: NCT02999087.
Related Papers
- → Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma(2014)60 cited
- → EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer.(2019)4 cited
- → The relationship between oral health and radiation-induced mucositis among patients with head and neck cancer(2018)1 cited
- [The timing of the appearance of oral mucositis induced by concurrent chemoradiotherapy with S-1 for head and neck cancer].(2014)
- → Incidence of mucositis in patients with head and neck squamous cell carcinoma treated with radiotherapy plus cetuximab: a pilot study(2012)